SEARCH

SEARCH BY CITATION

References

  • 1
    Hart S, Bailey E. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations. Ann Pharmacother 1996; 30: 113040.
  • 2
    Todd PA, Benfield P. Amoxicillin/clavulanic acid, an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990; 39: 264307.
  • 3
    Reading C, Cole M. Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11: 8527.
  • 4
    Reading C, Hepburn P. The inhibition of staphylococcal beta-lactamase by clavulanic acid. Biochem J 1979; 179: 6776.
  • 5
    Hunter PA, Coleman K, Fisher J et al. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother 1980; 6: 45570.
  • 6
    Miller JM, Baker CN, Thornsberry C. Inhibition of beta-lactamase in Neisseria gonorrheae by sodium clavulanate. Antimicrob Agents Chemother 1978; 14: 7946.
  • 7
    Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: an antibiotic combination: mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 12236.
  • 8
    Matheson I, Soderman P, and the Collaborative Group on Drug Use in Pregnancy. Preliminary results from Norway and Sweden. Eur J Clin Pharmacol 1988; 36: A111.
  • 9
    De Vigan C, De Walle HE, Cordier S et al. Therapeutic drug use during pregnancy: a comparison in four European countries. OECM Working Group. Occupational exposures and congenital anomalies. J Clin Epidemiol 1999; 52: 97782.
  • 10
    Pedler SJ, Bint AJ. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother 1985; 27: 50810.
  • 11
    Tampakoudis P, Kalachanis J, Grimbizis G, Andreu A, Mantalenakis S. Prophylactic administration of amoxicillin and clavulanic acid in pregnant women with premature rupture of membranes. J Chemother 1996; 8: 2904.
  • 12
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case–control teratologic study. Eur J Obstet Gynecol Reprod Biol 2001; 97: 18892.
  • 13
    Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 11328.
  • 14
    Moore KI, Persand TVN. The Developing Human Clinically Oriented Embryology. Philadelphia, PA: W.B. Saunders Co., 1993; 111.
  • 15
    Fleiss JL. Statistical Methods for Rates and Populations, 2nd edn. New York: John Wiley & Sons, 1981.
  • 16
    Baldwin JA, Schardein JL, Koshima Y. Reproduction studies of BRL 14151K and BRL 25000. Teratology and peri-and postnatal studies in rats. Chemotherapy 1983; 31: 23862.
  • 17
    Hirakawa T, Suzuki T, Sano Y et al. Reproduction studies in rats. Chemotherapy 1983; 31: 26372.
  • 18
    James PA, Hardy TL, Koshima Y. Reproduction studies of BRL 25000. Teratology studies in the pig. Chemotherapy 1983; 31: 2749.
  • 19
    Fortunato SJ, Bawdon RE, Swan KF, Bryant EC, Sobhi S. Transfer of Timentin (ticarcillin and clavulanic acid) across the in vitro perfused human placenta: comparison with other agents. Am J Obstet Gynecol 1992; 167: 15959.
  • 20
    Maberry MC, Trimmer KJ, Bawdon RE et al. Antibiotic concentration in maternal blood, cord blood and placental tissue in women with chorioamnionitis. Gynecol Obstet Invest 1992; 33: 1856.
  • 21
    Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group, 1977.
  • 22
    Stevenson RE, Hall JG, Goodman RM. Human Malformations and Related Anomalies, I. New York: Oxford University Press, 1993; 99.